![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing...
Sandoz reports first quarter 2024 sales Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5...
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG All proposals of Board of Directors approvedGilbert Ghostine re-elected as...
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches...
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules...
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes...
Sandoz reports fourth quarter 2023 sales and full-year 2023 results Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong fourth quarter performance, with...
Sandoz receives FDA approval for first and only denosumab biosimilars MEDIA RELEASE Wyost® (denosumab-bddz) and Jubbonti® (denosumab-bddz) interchangeable with and approved by FDA for all...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions